Chronic Lymphocytic Leukemia Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.A Study to Evaluate Efficacy, Safety, and Pharmacokinetics of XEMBIFY ® Plus Standard Medical Treatment (SMT) Compared to Placebo Plus SMT to Prevent Infections in Participants With Hypogammaglobulinemia and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia
Conditions: Hypogammaglobulinemia; Bacterial Infections; B-cell Chronic Lymphocytic Leukemia Interventions: Drug: Xembify; Drug: Placebo Sponsor: Grifols Therapeutics LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 9, 2022 Category: Research Source Type: clinical trials
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
Conditions: B-cell Lymphoma; Non-Hodgkin Lymphoma; B-cell Malignancy; Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL); Follicular Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Large B-cell Lymphoma Intervention: Biological: CTX112 Sponsor: CRISPR Therapeutics AG Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 9, 2022 Category: Research Source Type: clinical trials
A Study to Evaluate Efficacy, Safety, and Pharmacokinetics of XEMBIFY ® Plus Standard Medical Treatment (SMT) Compared to Placebo Plus SMT to Prevent Infections in Participants With Hypogammaglobulinemia and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia
Conditions: Hypogammaglobulinemia; Bacterial Infections; B-cell Chronic Lymphocytic Leukemia Interventions: Drug: Xembify; Drug: Placebo Sponsor: Grifols Therapeutics LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 9, 2022 Category: Research Source Type: clinical trials
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
Conditions: B-cell Lymphoma; Non-Hodgkin Lymphoma; B-cell Malignancy; Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL); Follicular Lymphoma; Mantle Cell Lymphoma; Marginal Zone Lymphoma; Large B-cell Lymphoma Intervention: Biological: CTX112 Sponsor: CRISPR Therapeutics AG Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 9, 2022 Category: Research Source Type: clinical trials
A Study to Evaluate Efficacy, Safety, and Pharmacokinetics of XEMBIFY ® Plus Standard Medical Treatment (SMT) Compared to Placebo Plus SMT to Prevent Infections in Participants With Hypogammaglobulinemia and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia
Conditions: Hypogammaglobulinemia; Bacterial Infections; B-cell Chronic Lymphocytic Leukemia Interventions: Drug: Xembify; Drug: Placebo Sponsor: Grifols Therapeutics LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 9, 2022 Category: Research Source Type: clinical trials
